This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00251-07v1 51/12/4351    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ambrose, P. G. Articles by Heine, H. S. Search for Related Content PubMed PubMed Citation Articles by Ambrose, P. G. Articles by Heine, H. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4351-4355, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00251-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics-Pharmacodynamics of Gatifloxacin in a Lethal Murine Bacillus anthracis Inhalation Infection Model

Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, New York,¹ School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York,² William S. Middleton Memorial VA Medical Center, Madison, Wisconsin,³ Emerging Infections and Fungal Pharmacodynamics Laboratory, Ordway Research Institute, Albany, New York,⁴ U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland⁵

Received 19 February 2007/ Returned for modification 13 May 2007/ Accepted 2 September 2007

We determined the pharmacokinetic-pharmacodynamic (PK-PD) measure most predictive of gatifloxacin efficacy and the magnitude of this measure necessary for survival in a murine Bacillus anthracis inhalation infection model. We then used population pharmacokinetic models for gatifloxacin and simulation to identify dosing regimens with high probabilities of attaining exposures likely to be efficacious in adults and children. In this work, 6- to 8-week-old nonneutropenic female BALB/c mice received aerosol challenges of 50 to 75 50% lethal doses of B. anthracis (Ames strain, for which the gatifloxacin MIC is 0.125 mg/liter). Gatifloxacin was administered at 6- or 8-h intervals beginning 24 h postchallenge for 21 days, and dosing was designed to produce profiles mimicking fractionated concentration-time profiles for humans. Mice were evaluated daily for survival. Hill-type models were fitted to survival data. To identify potentially effective dosing regimens, adult and pediatric population pharmacokinetic models for gatifloxacin and Monte Carlo simulation were used to generate 5,000 individual patient exposure estimates. The ratio of the area under the concentration-time curve from 0 to 24 h (AUC_0-24) to the MIC of the drug for the organism (AUC_0-24/MIC ratio) was the PK-PD measure most predictive of survival (R² = 0.96). The 50% effective dose (ED₅₀) and the ED₉₀ and ED₉₉ corresponded to AUC_0-24/MIC ratios of 11.5, 15.8, and 30, respectively, where the maximum effect was 97% survival. Simulation results indicate that a daily gatifloxacin dose of 400 mg for adults and 10 mg/kg of body weight for children gives a 100% probability of attaining the PK-PD target (ED₉₉). Sensitivity analyses suggest that the probability of PK-PD target attainment in adults and children is not affected by increases in MICs for strains of B. anthracis to levels as high as 0.5 mg/liter.

Published ahead of print on 17 September 2007.